KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Receivables (2016 - 2025)

NovoCure (NVCR) has disclosed Receivables for 12 consecutive years, with $66.5 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 62.93% to $66.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.5 million through Dec 2025, up 62.93% year-over-year, with the annual reading at $66.5 million for FY2025, 62.93% up from the prior year.
  • Receivables hit $66.5 million in Q4 2025 for NovoCure, down from $92.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $101.0 million in Q1 2022 to a low of $17.0 million in Q4 2021.
  • Historically, Receivables has averaged $47.5 million across 5 years, with a median of $39.1 million in 2024.
  • Biggest five-year swings in Receivables: tumbled 79.88% in 2022 and later soared 290.15% in 2023.
  • Year by year, Receivables stood at $17.0 million in 2021, then skyrocketed by 65.35% to $28.2 million in 2022, then dropped by 4.34% to $26.9 million in 2023, then skyrocketed by 51.47% to $40.8 million in 2024, then soared by 62.93% to $66.5 million in 2025.
  • Business Quant data shows Receivables for NVCR at $66.5 million in Q4 2025, $92.5 million in Q3 2025, and $46.1 million in Q2 2025.